Literature DB >> 15276198

Cellular control of gene expression by T-type cyclin/CDK9 complexes.

Judit Garriga1, Xavier Graña.   

Abstract

The family of Cyclin-Dependent Kinases (CDKs) can be subdivided into two major functional groups based on their roles in cell cycle and/or transcriptional control. This review is centered on CDK9, which is activated by T-type cyclins and cyclin K generating distinct Positive-Transcription Elongation Factors termed P-TEFb. P-TEFb positively regulates transcriptional elongation by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (RNA pol II), as well as negative elongation factors, which block elongation by RNA pol II shortly after the initiation of transcription. Work over the past few years has led to a dramatic increase in our understanding of how productive transcriptional elongation occurs. This review will briefly describe the mechanisms regulating the activity of T-type cyclin/CDK9 complexes and discuss how these complexes regulate gene expression. For further information, the reader is directed to excellent existing reviews on transcriptional elongation and HIV transcription.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15276198     DOI: 10.1016/j.gene.2004.05.007

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  69 in total

Review 1.  RNA polymerase II elongation control.

Authors:  Qiang Zhou; Tiandao Li; David H Price
Journal:  Annu Rev Biochem       Date:  2012-03-09       Impact factor: 23.643

2.  Transcriptional regulation of HIV-1 gene expression by p53.

Authors:  Ruma Mukerjee; Pier Paolo Claudio; J Robert Chang; Luis Del Valle; Bassel E Sawaya
Journal:  Cell Cycle       Date:  2010-11-15       Impact factor: 4.534

3.  Regulation of P-TEFb elongation complex activity by CDK9 acetylation.

Authors:  Junjiang Fu; Ho-Geun Yoon; Jun Qin; Jiemin Wong
Journal:  Mol Cell Biol       Date:  2007-04-23       Impact factor: 4.272

4.  Kaposi's sarcoma-associated herpesvirus K-cyclin interacts with Cdk9 and stimulates Cdk9-mediated phosphorylation of p53 tumor suppressor.

Authors:  Pei-Ching Chang; Mengtao Li
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

Review 5.  Functional evolution of cyclin-dependent kinases.

Authors:  John H Doonan; Georgios Kitsios
Journal:  Mol Biotechnol       Date:  2009-01-15       Impact factor: 2.695

6.  Tat-regulated expression of RNA interference: triggers for the treatment of HIV infection.

Authors:  Hoshang Unwalla; John J Rossi
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

7.  P-TEFb is not an essential elongation factor for the intronless human U2 snRNA and histone H2b genes.

Authors:  Joanne Medlin; Andrew Scurry; Alice Taylor; Fan Zhang; B Matija Peterlin; Shona Murphy
Journal:  EMBO J       Date:  2005-11-24       Impact factor: 11.598

8.  The positive transcription elongation factor b is an essential cofactor for the activation of transcription by myocyte enhancer factor 2.

Authors:  Masanori Nojima; Yehong Huang; Mudit Tyagi; Hung-Ying Kao; Koh Fujinaga
Journal:  J Mol Biol       Date:  2008-07-16       Impact factor: 5.469

9.  Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer.

Authors:  Hanghang Zhang; Somnath Pandey; Meghan Travers; Hongxing Sun; George Morton; Jozef Madzo; Woonbok Chung; Jittasak Khowsathit; Oscar Perez-Leal; Carlos A Barrero; Carmen Merali; Yasuyuki Okamoto; Takahiro Sato; Joshua Pan; Judit Garriga; Natarajan V Bhanu; Johayra Simithy; Bela Patel; Jian Huang; Noël J-M Raynal; Benjamin A Garcia; Marlene A Jacobson; Cigall Kadoch; Salim Merali; Yi Zhang; Wayne Childers; Magid Abou-Gharbia; John Karanicolas; Stephen B Baylin; Cynthia A Zahnow; Jaroslav Jelinek; Xavier Graña; Jean-Pierre J Issa
Journal:  Cell       Date:  2018-10-25       Impact factor: 41.582

10.  Selective control of gene expression by CDK9 in human cells.

Authors:  Judit Garriga; Hongbo Xie; Zoran Obradovic; Xavier Graña
Journal:  J Cell Physiol       Date:  2010-01       Impact factor: 6.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.